Spire Wealth Management’s ProShares UltraPro Short Russell2000 SRTY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-35
Closed -$1.63K – 2470
2025
Q3
$1.63K Buy
35
+1
+3% +$57 ﹤0.01% 2198
2025
Q2
$2.32K Hold
34
– – ﹤0.01% 2147
2025
Q1
$3.33K Hold
34
– – ﹤0.01% 2164
2024
Q4
$2.53K Buy
34
+2
+6% +$144 ﹤0.01% 2200
2024
Q3
$2.57K Hold
32
– – ﹤0.01% 1952
2024
Q2
$3.52K Hold
32
– – ﹤0.01% 1904
2024
Q1
$3.21K Buy
32
+1
+3% +$122 ﹤0.01% 2011
2023
Q4
$4.28K Hold
31
– – ﹤0.01% 1995
2023
Q3
$5.82K Hold
31
– – ﹤0.01% 1904
2023
Q2
$4.93K Buy
31
+1
+3% +$192 ﹤0.01% 2004
2023
Q1
$5.81K Buy
+30
New +$5.49K ﹤0.01% 1998
2022
Q3
– Sell
-30
Closed -$9K – 2561
2022
Q2
$9K Buy
+30
New +$7.46K ﹤0.01% 1963
2022
Q1
– Sell
-30
Closed -$5K – 2844
2021
Q4
$5K Hold
30
– – ﹤0.01% 2581
2021
Q3
$6K Hold
30
– – ﹤0.01% 2253
2021
Q2
$5K Hold
30
– – ﹤0.01% 2327
2021
Q1
$6K Buy
+30
New +$7.23K ﹤0.01% 2593

Other funds holding SRTY

Spire Wealth Management's SRTY Position: Q4 2025 in Review

Spire Wealth Management sold out of ProShares UltraPro Short Russell2000 (SRTY) in Q4 2025, closing a stake of 35 shares — an estimated $1.63K sold.

Spire Wealth Management first reported a position in SRTY in Q1 2021 and held it in 16 quarters. The position peaked at $9K in Q2 2022. 13 funds tracked by Wall St. Rank hold SRTY as of Q4 2025.

  • Spire Wealth Management reported no remaining ProShares UltraPro Short Russell2000 position as of Q4 2025 after selling out during the quarter.
  • Spire Wealth Management sold 35 ProShares UltraPro Short Russell2000 shares in Q4 2025, an estimated $1.63K.
  • Spire Wealth Management first reported a position in ProShares UltraPro Short Russell2000 in Q1 2021 and held it in 16 quarters.
  • Spire Wealth Management's ProShares UltraPro Short Russell2000 position peaked at $9K in Q2 2022.
  • 13 funds tracked by Wall St. Rank held ProShares UltraPro Short Russell2000 as of Q4 2025.

Based on Spire Wealth Management's 13F filing for Q4 2025, filed 14 Jan 2026.